OcuNex

Drug Profile

OcuNex

Alternative Names: Ono 9001

Latest Information Update: 15 Oct 1999

Price : $50

At a glance

  • Originator Telios Pharmaceuticals
  • Developer Ono Pharmaceutical; Telios Pharmaceuticals
  • Class Eye disorder therapies; Peptides
  • Mechanism of Action Peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Corneal ulcer

Most Recent Events

  • 15 Oct 1999 No-Development-Reported for Corneal ulcer in USA (Ophthalmic)
  • 12 Oct 1996 Discontinued-II for Corneal ulcer in Japan (Ophthalmic)
  • 12 Oct 1996 Discontinued-II for Corneal ulcer in South Korea (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top